Peter has a degree in Economics and is a chartered accountant having qualified with Arthur Young (now Ernst & Young) in London. He is Chief Executive of Cambridge Innovation Capital plc an investment fund focusing on technology investments arising from the University of Cambridge and the surrounding area.
In 1984, he joined his first technology business, Agricultural Genetics Ltd moving after 4 years to the diagnostic business Cambridge Life Sciences plc. Over a 2 year period he was instrumental in its reorganisation and trade sale, leaving at that time to join Enzymatix Ltd out of which was spun a number of technologies and businesses. One of these was Chiroscience Group plc where he was a co-founder and as Finance Director led the £102m initial public offering in March 1994.
In 1996 he co-founded the venture capital firm Merlin Biosciences as its UK Managing Director and was responsible for many early stage healthcare investments. Six of these were investments backing spin-outs from UK universities which he helped to build; four of these including Vectura plc are public companies and the private company BioVex was recently sold for a consideration of up to $1bn. Another investment was Arakis whom he joined in a full time capacity in 2004 and then subsequently led the negotiations for its sale to the Japanese biotech company Sosei for £106m. More recently he was a venture partner with the technology VC DFJ Esprit.
He is currently a Director of the Biotechnology Growth Trust plc a £280m investment trust investing in global biotechnology and Abcam plc where he is the Senior Independent Director.Back to our trustees